www.dailypolitical.com ·
Pyxis Oncology Nasdaqpyxs Issues Quarterly Earnings Results
Topic context
This topic has been covered 420036 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedPyxis Oncology is a clinical-stage biotech company; earnings miss is a company-specific event with no direct commodity or supply-chain impact. The stock movement reflects investor sentiment on pipeline progress and cash burn, not a sector-wide commercial mechanism. No scarcity or input cost channel identified.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Pyxis Oncology (NASDAQ:PYXS) reported Q1 2026 earnings loss of $0.37 per share, $0.02 below consensus estimate of $0.35.
- Stock fell $0.41 to $2.21 during midday trading with 1,062,627 shares traded.
- Market cap is $138.90 million; 52-week range $0.97 to $5.55.
- Analyst ratings: 6 buy, 1 hold, 1 sell; average target price $6.83.
- Institutional ownership 39.07%; several hedge funds recently acquired shares.
Related stories
fool.com
Keysight Keys Q2 2026 Earnings Transcript
proactiveinvestors.com.au
The Morning Catch Up Asx Set to Open Lower Ahead of Pivotal Nvidia Earnings
nbclosangeles.com
Spacex Confirms Plans for IPO
finance.yahoo.com
Biosig Technologies Q1 Earnings Call
zerohedge.com